Research To Practice | Oncology Videos

Featuring perspectives from Dr Neeraj Agarwal, Ms Kathy D Burns, Ms Susan K Roethke and Dr Sandy Srinivas, including the following topics: Introduction (0:00) Overview of Prostate Cancer (5:46) Intensification of Therapy for Localized Disease (35:19) Hormone-Sensitive Metastatic Disease (48:04) PARP Inhibitors (1:02:07) Radioligand Therapy (1:22:51) NCPD information and select publications

Featuring perspectives from Dr Michael J Overman, including the following topics: Introduction (0:00) Case: A woman in her mid 40s with microsatellite instability-high (MSI-H) colorectal adenocarcinoma metastatic to the brain receives pembrolizumab; KRAS G13D and somatic BRCA exon 11 mutations — Warren S Brenner, MD (16:27) Case: A woman in her late 50s with MSI-H Stage IIIB adenocarcinoma of the colon, BRAF V600E mutation — Eric H Lee, MD, PhD (23:20) Case: A woman in her early 70s with past medical history of diverticulitis and partial colectomy diagnosed with T1, microsatellite stable (MSS) cecal colon adenocarcinoma, minimum residual disease-negative after resection — Farshid Dayyani, MD, PhD (32:37) Case: A woman in her late 60s with past medical history of hypothyroidism has mass in right lung consistent with colorectal adenocarcinoma but no evidence of primary or other distant disease — Swati Vishwanathan, MD (42:58) Case: A woman in her mid 60s with multiregimen-relapsed RAS wild-type, HER2-positive metastatic rectal cancer, now receiving trastuzumab/tucatinib — Sunil Gandhi, MD (46:51) Case: A man in his mid 60s with MSS metastatic cecal adenocarcinoma and progressive disease on FOLFIRINOX/bevacizumab and capecitabine/bevacizumab maintenance — Dr Brenner (50:13) Case: A woman in her mid 60s with metastatic BRAF V600E-mutant colorectal adenocarcinoma, with circulating tumor DNA positivity after FOLFOX, heated intraperitoneal chemotherapy and colectomy/debulking surgery — Jeremy Lorber, MD (54:31) CME information and select publications

Featuring perspectives from Ms Courtney Arn, Dr David M O'Malley, Dr Richard T Penson and Ms Jaclyn Shaver, including the following topics: Introduction (0:00) Overview of Ovarian Cancer (4:50) Initial Management of Advanced Ovarian Cancer (26:41) Up-Front PARP Inhibitor Maintenance Therapy (33:10) Side Effects and Toxicities of PARP Inhibitors (37:07) Antibody-Drug Conjugates (1:02:13) Future Directions — Tumor Treating Fields (1:20:12) NCPD information and select publications

Featuring perspectives from Dr Joyce O'Shaughnessy, including the following topics: Introduction (0:00) HER2-Positive Metastatic Breast Cancer –– Professor Giuseppe Curigliano, MD, PhD (8:04) ASCO 2023 Preview (38:37) NCPD information and select publications

Featuring perspectives from Prof Sia Daneshmand, Dr Joshua J Meeks, Dr Matthew Milowsky and Prof J Alfred Witjes, moderated by Dr Arlene Siefker‑Radtke, including the following topics: Introduction (0:00) Current Role of Anti-PD-1/PD-L1 Antibodies in the Treatment of Non-Muscle-Invasive Bladder Cancer — Joshua J Meeks, MD, PhD (2:49) Contemporary Management of Muscle-Invasive Bladder Cancer — J Alfred Witjes, MD, PhD (26:30) Novel Strategies Under Investigation for Nonmetastatic Urothelial Bladder Cancer (UBC) — Sia Daneshmand, MD (48:02) Current and Future Up-Front Management of Metastatic UBC (mUBC) — Matthew Milowsky, MD (1:12:26) Selection and Sequencing of Therapy for Relapsed/Refractory mUBC — Arlene Siefker-Radtke, MD (1:33:25) CME information and select publications

Featuring perspectives from Dr Ahmed Omar Kaseb, Ms Blanca Ledezma, Dr Daneng Li and Ms Amanda K Wagner, including the following topics: Introduction (0:00) Overview of Hepatocellular Carcinoma (HCC) (3:37) First-Line Systemic Therapy for HCC (27:37) Therapy for Relapased HCC (41:43) Overview of Biliary Tract Cancers (54:10) First-Line Systemic Therapy for Biliary Tract Cancers (1:8:45) Targeted Treatment for Biliary Tract Cancers (1:11:25) NCPD information and select publications

Featuring perspectives from Dr John N Allan, Ms Jacqueline Broadway‑Duren, Ms Corinne Hoffman and Dr Adam S Kittai, including the following topics: Introduction (0:00) Overview of Chronic Lymphocytic Leukemia (CLL) (5:20) First-Line Therapy for CLL (32:06) Use of Venetoclax in Combination with an Anti-CD20 Antibody (49:16) Choice of BTK Inhibitor; BTK Inhibitor Toxicity (1:14:33) Noncovalent BTK Inhibitors (1:18:53) CAR T-Cell Therapy; Transformation (1:23:08) NCPD information and select publications

Featuring perspectives from Dr Himisha Beltran, Dr Stephen J Freedland, Dr Fred Saad and Dr Neal D Shore, moderated by Dr Matthew R Smith, including the following topics: Introduction (0:00) Management Approaches for Nonmetastatic Prostate Cancer — Dr Freedland (1:45) Optimizing the Care of Patients with Metastatic Hormone-Sensitive Prostate Cancer — Dr Saad (26:14) Therapeutic Considerations for Patients with Newly Diagnosed Metastatic CRPC (mCRPC) — Dr Shore (51:51) Contemporary Management of mCRPC in Patients Harboring a Homologous Recombination Repair Gene Alteration — Dr Smith (1:16:20) Current and Emerging Strategies in the Treatment of Recurrent mCRPC — Dr Beltran (1:36:47) CME information and select publications

Featuring perspectives from Dr Stephen V Liu, Ms Tara Plues, Ms Jillian Thompson and Dr Anne S Tsao, including the following topics: Introduction (0:00) Immunotherapy for Nonmetastatic and Metastatic Non-Small Cell Lung Cancer (NSCLC) (5:47) Future Directions — Tumor Treating Fields (37:30) Overview of Targeted Treatment for NSCLC (53:38) Targeted Treatment for NSCLC with an EGFR Mutation (1:10:48) EGFR Exon 20 Insertion Mutations (1:26:35) Targeted Treatment for NSCLC with a RET Fusion (1:37:40) Targeted Treatment for NSCLC with a KRAS G12C Mutation (1:46:45) NCPD information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Hepatobiliary Cancers — Facutly Presentation 2: Biliary Tract Cancers — Dr Richard S Finn CME information and select publications